World1 month ago
Study Reports Real-World Pembrolizumab Toxicity in TNBC
TOPLINE: In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received pembrolizumab developed immune-related adverse events — findings...
